CA2363965A1 - Protein-induced morphogenesis - Google Patents

Protein-induced morphogenesis Download PDF

Info

Publication number
CA2363965A1
CA2363965A1 CA002363965A CA2363965A CA2363965A1 CA 2363965 A1 CA2363965 A1 CA 2363965A1 CA 002363965 A CA002363965 A CA 002363965A CA 2363965 A CA2363965 A CA 2363965A CA 2363965 A1 CA2363965 A1 CA 2363965A1
Authority
CA
Canada
Prior art keywords
tissue
proteins
residues
matrix
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002363965A
Other languages
French (fr)
Other versions
CA2363965C (en
Inventor
Charles M. Cohen
Thangavel Kuberasampath
Roy H. L. Pang
Hermann Oppermann
David C. Rueger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2363965A1 publication Critical patent/CA2363965A1/en
Application granted granted Critical
Publication of CA2363965C publication Critical patent/CA2363965C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A61K6/50—Preparations specially adapted for dental root treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/28—Materials or treatment for tissue regeneration for liver reconstruction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to amino acid sequence data, structural features, homologies and various other data characterizing morphogenic proteins. There is also disclosed methods of producing these proteins form natural and recombinant sources and from synthetic constructs. The invention also relates to morphogenic devices comprising these proteins and a suitably modified tissue-specific matrix. Methods of inducing non-chondrogenic tissue growth in mammals are also disclosed.
The proteins are useful in inducing the developmental cascade of tissue morphogenesis for a variety of tissues in mammals different from bone or cartilage. The proteins of the morphogenic devices comprise a pair of folded polypeptides, the amino acid sequence of each comprises a sequence sharing at least 70% homology with the C-terminal seven-cysteine domain of human OP-1, mouse OP-1, human OP-2 or mouse OP-2, residues 38-139 of Seq. ID Nos. 5, 6, 7 or 8; or an essentially 102 amino acid sequence having cysteine residues at relative positions 1, 30, 34, 66, 67, 99 and 101 therein, wherein at least 70% of amino acid residues within said sequence are selected independently from residues occupying the corresponding positions within residues 38-139 of Seq. ID Nos., 5, 6, 7 or 8, or conservative substitutions of said corresponding residues.

Disclosed are 1) amino acid sequence data, structural features, homologies and various other data characterizing morphog-enic proteins, 2) methods of producing these proteins from natural and recombinant sources and from synthetic constructs, 3) morphogenic devices comprising these morphogenic proteins and a suitably modified tissue-specific matrix, and 4) methods of inducing non-chondrogenic tissue growth in a mammal.

Claims (5)

1. A composition comprising a) a biocompatible acellular matrix that provides as anchoring substratum for mammalian progenitor cells and is essentially free of substrates that inhibit morphogenesis; and b) a morphogen absorbed on said matrix at a concentration sufficient for inducing the developmental cascade of tissue-specific morphogenesis when said composition is disposed at a non-skeletal tissue locus in vivo, said matrix having components specific for said tissue locus.
2. The composition of claim 1, wherein said matrix is biodegradable and/or porous (being derived from organ-specific tissue or comprising collagen or cell attachment factors selected from glycosaminoglycans and proteoglycans).
3. A composition comprising a morphogen in association with a matrix derived from dehydrated non-skeletal tissue.
4. The composition of claim 1 wherein said matrix is derived from liver tissue or from demineralized dentin.
5. Use of the morphogen of claim 1 in a mammal for:
(a) preventing or inhibiting the formation of scar tissue, and regenerating skin tissue;
(b) the treatment of liver or blood disorders;
(c) increasing protenitor cell populations;
(d) stimulating the proliferation of differentiated cells;
(e) the treatment of osteoporosis;
(f) dentin regeneration;

(g) the healing of gastrointestinal ulcers;
(h) non-skeletal tissue replacement;
(i) neuroprotection or the treatment of degenerative nerve disease; and (j) the treatment of lung tissue damaged by emphyscema.
CA2363965A 1991-03-11 1992-03-11 Protein-induced morphogenesis Expired - Lifetime CA2363965C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66727491A 1991-03-11 1991-03-11
US667,274 1991-03-11
US75276491A 1991-08-30 1991-08-30
US752,764 1991-08-30
CA002104678A CA2104678C (en) 1991-03-11 1992-03-11 Protein-induced morphogenesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002104678A Division CA2104678C (en) 1991-03-11 1992-03-11 Protein-induced morphogenesis

Publications (2)

Publication Number Publication Date
CA2363965A1 true CA2363965A1 (en) 1992-09-17
CA2363965C CA2363965C (en) 2010-05-18

Family

ID=27099654

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2363965A Expired - Lifetime CA2363965C (en) 1991-03-11 1992-03-11 Protein-induced morphogenesis
CA002104678A Expired - Lifetime CA2104678C (en) 1991-03-11 1992-03-11 Protein-induced morphogenesis

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002104678A Expired - Lifetime CA2104678C (en) 1991-03-11 1992-03-11 Protein-induced morphogenesis

Country Status (2)

Country Link
US (3) US6565843B1 (en)
CA (2) CA2363965C (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586388B2 (en) * 1988-04-08 2003-07-01 Stryker Corporation Method of using recombinant osteogenic protein to repair bone or cartilage defects
US6919308B2 (en) * 1988-04-08 2005-07-19 Stryker Corporation Osteogenic devices
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US6495513B1 (en) * 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US20080233170A1 (en) * 1992-02-21 2008-09-25 Stryker Corporation Osteogenic Proteins
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU743510B2 (en) * 1997-05-05 2002-01-24 Stryker Corporation Therapies for acute renal failure
EP1988395A1 (en) 1997-05-30 2008-11-05 Curis, Inc. Methods for evaluating tissue morphogenesis and morphogenic activity
BR0214275A (en) 2001-11-19 2004-09-21 Scil Technology Gmbh Device having osteoconductive and osteoinductive properties
US7763270B2 (en) * 2002-09-10 2010-07-27 Scil Technology Gmbh Metal implant coated under reduced oxygen concentration with osteoinductive protein
WO2005077403A1 (en) * 2004-02-04 2005-08-25 Stryker Corporation Therapeutic methods using smads
WO2006029406A2 (en) * 2004-09-09 2006-03-16 Stryker Corporation Methods for treating bone tumors using bone morphogenic proteins
US20080020014A1 (en) * 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
ES2447516T3 (en) * 2006-12-21 2014-03-12 Stryker Corporation Sustained release formulations comprising BMP-7 crystals
US20150335400A1 (en) * 2009-06-17 2015-11-26 The Trustees Of Columbia University In The City Of New York Tooth scaffolds
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. Cell expansion
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2814981C3 (en) * 1978-04-07 1981-08-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Factor for stimulating the rate of proliferation of liver cells
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4472840A (en) * 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
DE3382562D1 (en) 1982-09-24 1992-06-25 Us Health ANIMAL TISSUE RECOVERY.
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
NZ210699A (en) 1984-01-04 1989-06-28 Int Genetic Eng Isolation of an osteogenic protein of the p3 immunologically related family
US4609551A (en) * 1984-03-20 1986-09-02 Arnold Caplan Process of and material for stimulating growth of cartilage and bony tissue at anatomical sites
US4608199A (en) * 1984-03-20 1986-08-26 Arnold Caplan Bone protein purification process
US4620327A (en) * 1984-07-05 1986-11-04 Caplan Arnold I Process of adapting soluble bone protein for use in stimulating osteoinduction
US4888366A (en) * 1984-10-24 1989-12-19 Collagen Corporation Inductive collagen-based bone repair preparations
US4721096A (en) * 1986-04-18 1988-01-26 Marrow-Tech Incorporated Process for replicating bone marrow in vitro and using the same
US4919939A (en) 1986-04-29 1990-04-24 Pharmetrix Corporation Periodontal disease treatment system
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
ZA874681B (en) 1986-07-01 1988-04-27 Genetics Inst Novel osteoinductive factors
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US4877864A (en) 1987-03-26 1989-10-31 Genetics Institute, Inc. Osteoinductive factors
US5543394A (en) 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5186931A (en) * 1986-08-06 1993-02-16 Ajinomoto Co., Inc. Composition and method for supporting bone marrow transplantation
US5124316A (en) 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
US5035901A (en) * 1987-10-09 1991-07-30 University Of Kansas Bone inducing agent from a human osteosarcoma cell line
DE68925773T2 (en) * 1988-04-08 1996-10-17 Stryker Corp OSTEOGENIC DEVICES
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
KR900700617A (en) 1988-04-08 1990-08-16 브루스 엠. 에이센 Bone and Cartilage Inducing Compositions
US4975526A (en) 1989-02-23 1990-12-04 Creative Biomolecules, Inc. Bone collagen matrix for zenogenic implants
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5002488A (en) 1988-04-12 1991-03-26 Hadaco, Ltd. Dental implants with resorption preventing means
US4904259A (en) * 1988-04-29 1990-02-27 Samuel Itay Compositions and methods for repair of cartilage and bone
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
EP0368992B1 (en) 1988-05-31 1995-02-15 Biotechnology Australia Pty. Ltd. Actions of hormones
US4935497A (en) 1988-09-06 1990-06-19 Northwestern University Dentin chondrogenic inductive agent
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US4946437A (en) * 1988-12-02 1990-08-07 Bar-Ilan University Method for the stimulation of bone marrow cells
JPH03505218A (en) 1989-02-23 1991-11-14 サイトタクシス、インコーポレーテッド Periodontal and bone regeneration factors, materials and methods
CA2030518C (en) 1989-03-28 2000-03-21 Elizabeth A. Wang Osteoinductive compositions
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
WO1991001720A1 (en) * 1989-08-07 1991-02-21 Herman Wade Schlameus Composition and method of promoting hard tissue healing
EP0416578B1 (en) 1989-09-06 1996-07-31 Takeda Chemical Industries, Ltd. Protein, DNA and use thereof
US5290558A (en) * 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
US5073373A (en) * 1989-09-21 1991-12-17 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
ATE167486T1 (en) 1989-10-17 1998-07-15 Stryker Corp OSTEOGENIC DEVICES
US5236456A (en) 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
US5108989A (en) * 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
US5197882A (en) 1990-05-14 1993-03-30 Gary R. Jernberg Periodontal barrier and method for aiding periodontal tissue regeneration agents
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
EP0652951B1 (en) 1990-06-15 1999-09-01 Carnegie Institution Of Washington GDF-1and UOG-1 proteins
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US5652337A (en) * 1991-03-11 1997-07-29 Creative Biomolecules, Inc. OP-3-induced morphogenesis
AU660019B2 (en) 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
US6090776A (en) * 1991-03-11 2000-07-18 Creative Bio Molecules, Inc. Morphogen treatment of organ implants
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
EP0592562B1 (en) 1991-06-25 1999-01-07 Genetics Institute, Inc. Bmp-9 compositions
CA2116562C (en) 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
DE69233022T2 (en) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge RECOMBINANT BONE MORPHOGENETIC PROTEIN HETERODIMERS, COMPOSITIONS AND METHODS OF USE
ATE162078T1 (en) 1992-09-16 1998-01-15 Creative Biomolecules Inc MORPHOGEN-INDUCED LIVER REGENERATION
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US20030032586A1 (en) 1997-05-15 2003-02-13 David C. Rueger Compositions for morphogen-induced osteogenesis
AU1122099A (en) 1997-10-27 1999-05-17 Curis, Inc. Enhancement of morphogen activity
JP2000119192A (en) 1998-10-09 2000-04-25 Aventis Pharma Ltd Mature type protein having antagonistic activity for bone morphogenetic protein
US20030104977A1 (en) 2000-03-31 2003-06-05 Ugo Ripamonti Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors
US20040126375A1 (en) * 2001-01-12 2004-07-01 John Langenfeld Bone morphogenetic protein-2 in the treatment and diagnosis of cancer

Also Published As

Publication number Publication date
US6531445B1 (en) 2003-03-11
CA2104678A1 (en) 1992-09-12
US7196056B2 (en) 2007-03-27
CA2104678C (en) 2002-05-14
CA2363965C (en) 2010-05-18
US20040102373A1 (en) 2004-05-27
US6565843B1 (en) 2003-05-20

Similar Documents

Publication Publication Date Title
CA2363965A1 (en) Protein-induced morphogenesis
Helm et al. Utilization of type I collagen gel, demineralized bone matrix, and bone morphogenetic protein-2 to enhance autologous bone lumbar spinal fusion
Chenard et al. Bone morphogenetic proteins in craniofacial surgery: current techniques, clinical experiences, and the future of personalized stem cell therapy
Ripamonti et al. Tissue morphogenesis and regeneration by bone morphogenetic proteins
US5733878A (en) Morphogen-induced periodontal tissue regeneration
JP4895826B2 (en) Bone morphogenetic protein-2 positive modulator
CA1259914A (en) Methods of bone repair using collagen
Malemud The role of growth factors in cartilage metabolism
Vukičević et al. Discovery and clinical applications of bone morphogenetic proteins
Si et al. Induction of new bone by ceramic bovine bone with recombinant human bone morphogenetic protein 2 and transforming growth factor ß
US20220016206A1 (en) Isoform nell-1 peptide
CA2519174A1 (en) Improved osteoinductive materials
Bab et al. Polypeptide factors regulating osteogenesis and bone marrow repair
Dayoub et al. Human mesenchymal stem cells transduced with recombinant bone morphogenetic protein-9 adenovirus promote osteogenesis in rodents
EP2708246B1 (en) Growth factor anchoring type bone graft material, method for producing growth factor anchoring type bone graft material, kit for producing growth factor anchoring type bone graft material.
CA2060208C (en) Wound healing
Becker Augmentation of regenerative healing in man: A possible alternative to prosthetic implantation
Ohba et al. Tissue engineering of bone and cartilage
Seyedin Osteoinduction: A report on the discovery and research of unique protein growth factors mediating bone development
AU2003218463A1 (en) Bone generation by gene therapy
JP2000119192A (en) Mature type protein having antagonistic activity for bone morphogenetic protein
EP1591526A2 (en) Frazzled nucleotide sequences, expression products, compositions and uses
Murata et al. Bone induction in subcutaneous tissue in rats by a newly developed DNA-coated atelocollagen and bone morphogenetic protein
US20030235564A1 (en) Compositions and devices comprising or encoding the Run x2 protein and method of use
WO2023171808A1 (en) Therapeutic agent for spinal cord injury

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry